LifeCycle Pharma A/S announced successful completion of rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA,
AUSTRALIA OR JAPAN 

Company Announcement no. 17/2008
To: OMX Nordic Exchange Copenhagen	      	   Hørsholm, Denmark, April 17, 2008

 
LifeCycle Pharma A/S announced successful completion of rights issue

Hørsholm, Denmark, April 17, 2008; LifeCycle Pharma A/S (OMX: LCP) today
announced the successful completion of its rights issue.  The rights issue has
been 99.62 % subscribed with 23,987,771 offered new shares of DKK 1 nominal
value subscribed at DKK 17 per share.  The gross proceeds to LCP from the right
issue will be DKK 407.8 million, and the net proceeds will be approximately DKK
375.4 million. 

The new shares will carry rights and be eligible for dividends as from the date
the capital increase is registered with the Danish Commerce and Companies
Agency, which has taken place today. 

Following registration of 23,987,771 new shares of nominal value DKK 1 each,
the nominal value of LCP's share capital totals DKK 56,092,945 corresponding to
56,092,945  shares of nominal value DKK 1 each. 

It is expected that the new shares will be listed on the OMX Nordic Exchange
Copenhagen on Monday, April 21, 2008, under the securities code of the existing
shares, DK0060048148. 

Joint Global Coordinators and Lead Managers, Danske Markets (division of Danske
Bank A/S)  and UBS Limited, have notified the company that no stabilization has
taken place in relation to the preemptive rights issued by LCP. 

About LifeCycle Pharma A/S (“LCP”) 
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations. 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN THE UNITED STATES, CANADA,
AUSTRALIA OR JAPAN 

This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, Fenoglide™, currently on the U.S. market and a
diversified near- and medium-term pipeline, including five product candidates
in clinical trials and three in preclinical stages of development. LCP is
listed on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX:
LCP). For further information, please visit www.lcpharma.com. 

For further information please contact:

 
LifeCycle Pharma A/S
Hans Christian Teisen 
EVP  & CFO
+45 20 30 69 85;  
E-mail: hct@lcpharma.com
	


Disclaimer
This announcement is not a solicitation or an invitation to invest in LifeCycle
Pharma A/S. Any subscription for shares shall be based on the offering circular
prepared by the Company in connection with the Offering. These materials are
not an offer for sale of securities.  The securities have not been registered
under the U.S. Securities Act of 1933, as amended (the “Securities Act”) and
may not be offered or sold in the United States absent registration or an
exemption from the registration requirements of the Securities Act.  Any public
offering of securities will be made by means of a prospectus that may be
obtained from the issuer or selling security holder and that will contain
detailed information about the company and management, as well as financial
statements. 

In any EEA Member State that has implemented Directive 2003/71/EC (together
with any applicable implementing measures in any member State, the “Prospectus
Directive”), this communication is only addressed to and is only directed at
qualified investors in that Member State within the meaning of the Prospectus
Directive. 

This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) to investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 ((i) and (ii) above together being referred to
as “relevant persons”).  The securities are only available to, and any
invitation, offer or agreement to subscribe, purchase or otherwise acquire such
securities will be engaged in only with, relevant persons.  Any person who is
not a relevant person should not act or rely on this document or any of its
contents.